Noninvasive diagnostic methods of liver fibrosis in patients with primary biliary cirrhosis and primary sclerosing cholangitis: role of indirect serological markers

Aim of investigation. Considering prognostic value and dynamic nature of liver fibrosis in chronic cholestatic diseases: primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), severity assessment by liver biopsy and/or noninvasive methods should be obligatory component of the investigation plan during patient follow-up to estimate treatment response. The aim of the present study was to evaluate diagnostic value of noninvasive tests based on indirect liver fibrosis serological markers for the estimation of fibrosis severity in PBC and PSC. Materials and methods. Original study was based on retrospective evaluation of 95 patients with PBC and 27 patients with PSC. According to routine laboratory test data and abdominal ultrasound, indexes of AST to ALT ratio (AAR); AST to platelet count ratio (APRI); platelet count to the spleen diameter ratio - PLT/ SPD and Fibrosis-4 score index (FIB-4) were calculated. All patients underwent liver biopsy with fibrosis stage assessment in biopsy specimen (METAVIR scale). Diagnostic value of estimated indexes was evaluated and compared by ROC-analysis with ROC-curve plotting and calculation of the area under the ROC-curve (AUROC). Results. In PBC group (median age Me [interquartile range] was 54 years [49-62]) 50,5% (n=48) of patients had significant liver fibrosis (F≥2) and 21,1% (n=20) - liver cirrhosis (F4). In PSC group (Me=40 [28-50] years) 63% of patients (n=17) had severe fibrosis (F≥2) and 33,4% (n=9) - and liver cirrhosis (F4) respectively. PLT/SPD index provided the highest AUROC values at significant fibrosis (F≥2), severe fibrosis (F≥3) and liver cirrhosis (F4) in PBC group (0,763 [95% CI 0,664- 0,861], 0,764 [0,662-0,866], and 0,805 [0,694-0,915], respectively). However in PSC group, highest AUROC was found for FIB-4 index (0,844 [0,682-1,000], 0,845 [0,698-0,993], and 0,785 [0,594-0,975], respectively). Conclusion. Application of FIB-4 index in PSC allows to reveal significant liver fibrosis stage (F≥2) with high accuracy (80,7%). Efficacy of other indexes (AAR, APRI, and PLT/SPD) in these patients, as well as AAR, APRI, FIB-4, and PLT/SPD indexes in PBC, should be characterized as quite low that makes their clinical application inexpedient.

первичный билиарный цирроз, первичный склерозирующий холангит, биопсия печени, сывороточные маркёры фиброза

1. Corpechot C. Utility of noninvasive markers of fibrosis in cholestatic liver diseases. Clin Liver Dis 2016; 20(1):14358.

2. Poupon R. Noninvasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis. Dig Dis 2015; 33 (Suppl. 2):115-7.

3. Ивашкин В.Т., Павлов Ч.С. Фиброз печени. М.: ГЭОТАР-Медиа, 2011.

4. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. European Association for the Study of the Liver. J Hepatol 2009; 51(2):237-67.

5. Rockey D.C., Caldwell S.H., Goodman Z.D., Nelson R.C., Smith A.D.; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49(3):1017-44.

6. Castera L., Pinzani M. Noninvasive assessment of liver fi brosis: are we ready? Lancet 2010; 375(9724):1419-20.

7. Goodman Z.D. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007; 47(4):598-607.

8. EASL-ALEH Clinical Practice Guidelines: Noninvasive tests for evaluation of liver disease severity and prognosis. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. J Hepatol 2015; 63(1):237-64.

9. Duarte-Rojo A., Altamirano J.T., Feld J.J. Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. Ann Hepatol 2012; 11 (4):426-39.

10. Castera L. Hepatitis B: are noninvasive markers of liver fibrosis reliable? Liver Int 2014; 34 (Suppl. 1):91-6.

11. Fitzpatrick E., Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J Gastroenterol 2014; 20(31):10851-63.

12. Chrostek L., Panasiuk A. Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol 2014; 20 (25):8018-23.

13. Ивашкин В.Т., Широкова Е.Н., Маевская М.В., Павлов Ч.С., Шифрин О.С., Маев И.В., Трухманов А.С. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза. Рос журн гастроэнтерол гепатол колопроктол 2015; 25(2):41-57.

14. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31(5):929-38.

15. Sterling R.K., Lissen E., Clumeck N. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43(6):1317-25.

16. Testa R., Testa E., Giannini E., Borro P., Milazzo S., Isola L., et al. Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. J Intern Med 2006; 260(2):142-50.

17. Герасимов А.Н. Медицинская статистика. М.: ООО «Медицинское информационное агентство», 2007.

18. Gerasimov A.N. Medical statistics. M.: LLC «Meditsinskoye informatsionnoye agentstvo», 2007.

19. Alempijevic T., Krstic M., Jesic R. Biochemical markers for noninvasive assessment of disease stage in patients with primary biliary cirrhosis. World J Gastroenterol 2009; 15(5):591-4.

20. Lee H.H., Seo Y.S., Um S.H., Won N.H., Yoo H., Jung E.S., et al. Usefulness of noninvasive markers for predicting significant fibrosis in patients with chronic liver disease. J Korean Med Sci 2010; 25(1):67-74.

21. Corpechot C., Gaouar F., El Naggar A., Kemgang A., Wendum D., Poupon R., et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 2014; 146(4):970-9.

22. Corpechot C., Carrat F., Poujol-Robert A., Gaouar F., Wendum D., Chazouillères O., Poupon R. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012; 56(1):198-208.

23. Färkkilä M., Rautiainen H., Karkkainen P., et al. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. Liver Int 2008; 28 (6):787-97.

24. Floreani A., Cazzagon N., Martines D., Cavalletto L., Baldo V., Chemello L. Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. Dig Liver Dis 2011; 43(11):887-92.

25. Hernandez-Gea V., Friedman S.L. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6:425-56.